These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 16838769)

  • 1. Calcinosis cutis in a patient with eosinophilia-myalgia syndrome: case report.
    Smith E; Gordon M; Lebwohl M
    Cutis; 2006 Jun; 77(6):361-4. PubMed ID: 16838769
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Simultaneous development of two cases of eosinophilia-myalgia syndrome with the same lot of L-tryptophan in Japan.
    Mizutani T; Mizutani H; Hashimoto K; Nakamura Y; Kishida M; Taniguchi H; Murata M; Kuzuhara S; Shimizu M
    J Am Acad Dermatol; 1991 Sep; 25(3):512-7. PubMed ID: 1918490
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Acute respiratory failure as a manifestation of eosinophilia-myalgia syndrome associated with L-tryptophan intake].
    Grangeia Tde A; Schweller M; Paschoal IA; Zambon L; Pereira MC
    J Bras Pneumol; 2007; 33(6):747-51. PubMed ID: 18200378
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Upper extremity contractures in a patient with eosinophilia-myalgia syndrome.
    Marchman HB; Gleason CB; Shaw JC
    Arch Phys Med Rehabil; 1991 Nov; 72(12):1029-30. PubMed ID: 1953317
    [TBL] [Abstract][Full Text] [Related]  

  • 5. L-tryptophan-related eosinophilia-myalgia syndrome possibly associated with a chronic B-lymphocytic leukemia.
    Böhme A; Wolter M; Hoelzer D
    Ann Hematol; 1998 Nov; 77(5):235-8. PubMed ID: 9858150
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Head and neck manifestations of eosinophilia-myalgia syndrome.
    Levine B; Lanza DC; Ficco A; Freundlich B
    Ann Otol Rhinol Laryngol; 1995 Feb; 104(2):90-9. PubMed ID: 7857025
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Eosinophilia myalgia syndrome.
    Blackburn WD
    Semin Arthritis Rheum; 1997 Jun; 26(6):788-93. PubMed ID: 9213377
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Demyelinating polyneuropathy in eosinophilia-myalgia syndrome.
    Donofrio PD; Stanton C; Miller VS; Oestreich L; Lefkowitz DS; Walker FO; Ely EW
    Muscle Nerve; 1992 Jul; 15(7):796-805. PubMed ID: 1323757
    [TBL] [Abstract][Full Text] [Related]  

  • 9. L-tryptophan and the eosinophilia-myalgia syndrome: current understanding of the etiology and pathogenesis.
    Varga J; Jimenez SA; Uitto J
    J Invest Dermatol; 1993 Jan; 100(1):97S-105S. PubMed ID: 8423409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [A case of the eosinophilia-myalgia syndrome].
    Ishikawa A; Akahosi T; Okada J; Kondo H; Kasiwazaki S
    Ryumachi; 1992 Aug; 32(4):327-30; discussion 330-2. PubMed ID: 1411794
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Post-epidemic eosinophilia-myalgia syndrome associated with L-tryptophan.
    Allen JA; Peterson A; Sufit R; Hinchcliff ME; Mahoney JM; Wood TA; Miller FW; Whitfield ML; Varga J
    Arthritis Rheum; 2011 Nov; 63(11):3633-9. PubMed ID: 21702023
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chronic fatigue: a peculiar evolution of eosinophilia myalgia syndrome following treatment with L-tryptophan in four Italian adolescents.
    Priori R; Conti F; Luan FL; Arpino C; Valesini G
    Eur J Pediatr; 1994 May; 153(5):344-6. PubMed ID: 8033924
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Review of L-tryptophan and eosinophilia-myalgia syndrome.
    Roufs JB
    J Am Diet Assoc; 1992 Jul; 92(7):844-50. PubMed ID: 1624654
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epidemiologic studies of the association of L-tryptophan with the eosinophilia-myalgia syndrome: a critique.
    Shapiro S
    J Rheumatol Suppl; 1996 Oct; 46():44-58; discussion 58-9. PubMed ID: 8895181
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dystrophic calcinosis cutis in pseudoxanthoma elasticum.
    Federico A; Weinel S; Fabre V; Callen JP
    J Am Acad Dermatol; 2008 Apr; 58(4):707-10. PubMed ID: 18342721
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Eosinophilic hepatitis: a new feature of the clinical spectrum of the eosinophilia-myalgia syndrome.
    Martinez-Osuna P; Espinoza CG; Cuellar ML; Cabrera GE; Silveira LH; Espinoza LR
    Clin Rheumatol; 1994 Sep; 13(3):528-32. PubMed ID: 7835024
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathophysiology of the eosinophilia-myalgia syndrome.
    Silver RM
    J Rheumatol Suppl; 1996 Oct; 46():26-36. PubMed ID: 8895179
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tryptophan contaminants associated with eosinophilia-myalgia syndrome. The Eosinophilia-Myalgia Studies of Oregon, New York and New Mexico.
    Philen RM; Hill RH; Flanders WD; Caudill SP; Needham L; Sewell L; Sampson EJ; Falk H; Kilbourne EM
    Am J Epidemiol; 1993 Aug; 138(3):154-9. PubMed ID: 8356958
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 1,1'-Ethylidenebis[L-tryptophan], an impurity in L-tryptophan associated with eosinophilia-myalgia syndrome, stimulates type I collagen gene expression in human fibroblasts in vitro.
    Zangrilli JG; Mayeno AN; Vining V; Varga J
    Biochem Mol Biol Int; 1995 Nov; 37(5):925-33. PubMed ID: 8624499
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Movement disorders in the eosinophilia-myalgia syndrome: tremor, myoclonus, and myokymia.
    Kaufman LD; Kaufman MA; Krupp LB
    J Rheumatol; 1995 Jan; 22(1):157-60. PubMed ID: 7699663
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.